O Shaughnessy Asset Management LLC Sells 561 Shares of Eli Lilly and Company (NYSE:LLY)

O Shaughnessy Asset Management LLC lessened its stake in Eli Lilly and Company (NYSE:LLY) by 0.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 107,976 shares of the company’s stock after selling 561 shares during the period. Eli Lilly and Company comprises about 0.7% of O Shaughnessy Asset Management LLC’s portfolio, making the stock its 21st biggest position. O Shaughnessy Asset Management LLC’s holdings in Eli Lilly and Company were worth $83,357,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Prevail Innovative Wealth Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $3,628,000. Physician Wealth Advisors Inc. grew its holdings in Eli Lilly and Company by 23.2% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,406 shares of the company’s stock worth $1,085,000 after acquiring an additional 265 shares during the period. Martin Currie Ltd. grew its holdings in Eli Lilly and Company by 137.9% during the 4th quarter. Martin Currie Ltd. now owns 37,422 shares of the company’s stock worth $28,890,000 after acquiring an additional 21,689 shares during the period. RWA Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 2.3% in the 4th quarter. RWA Wealth Partners LLC now owns 45,191 shares of the company’s stock worth $34,888,000 after acquiring an additional 1,028 shares in the last quarter. Finally, Schroder Investment Management Group grew its stake in Eli Lilly and Company by 0.3% during the fourth quarter. Schroder Investment Management Group now owns 1,686,582 shares of the company’s stock worth $1,302,041,000 after purchasing an additional 5,369 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $820.30 on Friday. The company has a market capitalization of $777.78 billion, a PE ratio of 70.05, a PEG ratio of 1.40 and a beta of 0.34. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The stock’s 50 day moving average price is $844.31 and its 200-day moving average price is $836.37. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its board has approved a share repurchase program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Citigroup cut their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Bank of America reiterated a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a research report on Thursday, January 16th. Finally, Truist Financial upped their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.